# Eton Pharmaceuticals, Inc.: overview ETON · Nasdaq · CIK 1710340 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/eton.md) · [Financials](/companies/eton/financials.md) · [Filings](/companies/eton/filings.md) · [Insiders](/companies/eton/insiders.md) Latest reported revenue: [$37.6m](/filings/0001437749-26-027684.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-027684). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [10.3](/filings/0001437749-25-033619.md) | [11.6 d](/filings/0001437749-26-009059.md) | [17.3](/filings/0001437749-26-017064.md) | [18.9](/filings/0001437749-26-027684.md) | [22.5](/filings/0001437749-25-033619.md) | [21.3 d](/filings/0001437749-26-009059.md) | [24.3](/filings/0001437749-26-017064.md) | [37.6](/filings/0001437749-26-027684.md) | | Gross margin | % | [61.0%](/filings/0001437749-25-033619.md) | [55.6% d](/filings/0001437749-26-009059.md) | [57.1%](/filings/0001437749-26-017064.md) | [63.0%](/filings/0001437749-26-027684.md) | [35.0%](/filings/0001437749-25-033619.md) | [61.6% d](/filings/0001437749-26-009059.md) | [60.7%](/filings/0001437749-26-017064.md) | [67.6%](/filings/0001437749-26-027684.md) | | Operating margin | % | [4.9%](/filings/0001437749-25-033619.md) | [5.4% d](/filings/0001437749-26-009059.md) | [(2.7%)](/filings/0001437749-26-017064.md) | [(7.8%)](/filings/0001437749-26-027684.md) | [(6.1%)](/filings/0001437749-25-033619.md) | [11.6% d](/filings/0001437749-26-009059.md) | [9.9%](/filings/0001437749-26-017064.md) | [34.0%](/filings/0001437749-26-027684.md) | | Net margin | % | [6.1%](/filings/0001437749-25-033619.md) | [(5.1%) d](/filings/0001437749-26-009059.md) | [(9.1%)](/filings/0001437749-26-017064.md) | [(13.7%)](/filings/0001437749-26-027684.md) | [(8.6%)](/filings/0001437749-25-033619.md) | [7.0% d](/filings/0001437749-26-009059.md) | [6.4%](/filings/0001437749-26-017064.md) | [30.8%](/filings/0001437749-26-027684.md) | | Diluted EPS | $ per share | [0.02](/filings/0001437749-25-033619.md) | not reported | [(0.06)](/filings/0001437749-26-017064.md) | [(0.10)](/filings/0001437749-26-027684.md) | [(0.07)](/filings/0001437749-25-033619.md) | not reported | [0.05](/filings/0001437749-26-017064.md) | [0.35](/filings/0001437749-26-027684.md) | | Free cash flow | $m | [3.0 d](/filings/0001437749-25-033619.md) | [(0.8) d](/filings/0001437749-26-009059.md) | [2.1](/filings/0001437749-26-017064.md) | [8.0 d](/filings/0001437749-26-027684.md) | [11.7 d](/filings/0001437749-25-033619.md) | [(11.6) d](/filings/0001437749-26-009059.md) | [7.3](/filings/0001437749-26-017064.md) | [7.3 d](/filings/0001437749-26-027684.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [21.8](/filings/0001437749-24-007853.md) | [21.3](/filings/0001437749-25-008136.md) | [31.6](/filings/0001437749-26-009059.md) | [39.0](/filings/0001437749-26-009059.md) | [80.0](/filings/0001437749-26-009059.md) | | Gross margin | % | [87.1%](/filings/0001437749-24-007853.md) | [67.4%](/filings/0001437749-25-008136.md) | [66.6%](/filings/0001437749-26-009059.md) | [60.0%](/filings/0001437749-26-009059.md) | [53.5%](/filings/0001437749-26-009059.md) | | Operating margin | % | [(6.8%)](/filings/0001437749-24-007853.md) | [(38.9%)](/filings/0001437749-25-008136.md) | [(3.8%)](/filings/0001437749-26-009059.md) | [(6.7%)](/filings/0001437749-26-009059.md) | [(1.1%)](/filings/0001437749-26-009059.md) | | Net margin | % | [(9.0%)](/filings/0001437749-24-007853.md) | [(42.4%)](/filings/0001437749-25-008136.md) | [(3.0%)](/filings/0001437749-26-009059.md) | [(9.8%)](/filings/0001437749-26-009059.md) | [(5.8%)](/filings/0001437749-26-009059.md) | | Diluted EPS | $ per share | [(0.08)](/filings/0001493152-22-006990.md) | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(4.7)](/filings/0001437749-24-007853.md) | [4.8](/filings/0001437749-25-008136.md) | [6.8](/filings/0001437749-26-009059.md) | [0.9](/filings/0001437749-26-009059.md) | [10.2](/filings/0001437749-26-009059.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/eton/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2021-04-12 | [Harrow Health, Inc.](/insiders/1360214.md) | 10% owner | Sale (S) | 1,518,000 | $7.00 | $10.6m | [Form 4](/filings/0001493152-21-008584.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $103.5m | 2,860,000 | | Unchanged | | [EcoR1 Capital, LLC](/funds/1587114.md) | 2026-06-30 | $78.6m | 2,171,938 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $68.6m | 1,895,833 | | Added +178,547 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $42.6m | 1,175,951 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $42.6m | 1,175,951 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $35.4m | 976,570 | | Reduced −17,519 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $27.8m | 767,972 | | Added +290,015 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $25.4m | 701,786 | | Added +171,571 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $23.6m | 652,303 | | Added +74,637 | | [OBERWEIS ASSET MANAGEMENT INC/](/funds/937886.md) | 2026-06-30 | $18.2m | 501,600 | | Added +62,300 | ## Recent filings [All 415 filings](/companies/eton/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-14 | 11:15 ET | [8-K](/filings/0001437749-26-032600.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001437749-26-032600 | | 2026-09-28 | 11:15 ET | [8-K](/filings/0001437749-26-031281.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-031281 | | 2026-08-13 | 20:16 ET | [10-Q](/filings/0001437749-26-027684.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027684 | | 2026-08-13 | 20:10 ET | [8-K](/filings/0001437749-26-027672.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-027672 | | 2026-08-05 | 11:00 ET | [8-K](/filings/0001437749-26-025781.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001437749-26-025781 | | 2026-08-04 | 11:00 ET | [8-K](/filings/0001437749-26-025506.md) | 5.02 Departure or appointment of officers or directors | 0001437749-26-025506 | | 2026-07-29 | 11:00 ET | [8-K](/filings/0001437749-26-024746.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-024746 | | 2026-06-09 | 20:31 ET | [8-K](/filings/0001437749-26-020005.md) | 5.07 Shareholder vote results | 0001437749-26-020005 | | 2026-05-19 | 20:45 ET | [8-K](/filings/0001437749-26-017799.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001437749-26-017799 | | 2026-05-14 | 20:17 ET | [10-Q](/filings/0001437749-26-017064.md) | Quarterly report, period 2026-03-31 | 0001437749-26-017064 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-009059.md), filed Mar 19, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8258802a-6862-475d-9093-22a6c90f1f39) ## About the filer - CIK: 1710340 - Tickers: ETON - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.